Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 1 to 10 of 470 total matches.

Ozenoxacin 1% Cream (Xepi) for Impetigo

   
The Medical Letter on Drugs and Therapeutics • Apr 22, 2019  (Issue 1570)
Ozenoxacin 1% Cream (Xepi) for Impetigo The FDA has approved a 1% cream formulation ...
The FDA has approved a 1% cream formulation of ozenoxacin (Xepi – Cutanea), a nonfluorinated quinolone antibiotic, for treatment of impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in patients ≥2 months old.
Med Lett Drugs Ther. 2019 Apr 22;61(1570):63-4 | Show Introduction Hide Introduction

Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection

   
The Medical Letter on Drugs and Therapeutics • May 31, 2021  (Issue 1625)
Cabotegravir/Rilpivirine (Cabenuva) for HIV-1 Infection The FDA has approved Cabenuva (Vii ...
The FDA has approved Cabenuva (ViiV Healthcare), an extended-release formulation of the new integrase strand transfer inhibitor (INSTI) cabotegravir copackaged with an extended-release formulation of the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine, as a once-monthly complete regimen for intramuscular (IM) treatment of adults with HIV-1 infection who are virologically suppressed (HIV-1 RNA...
Med Lett Drugs Ther. 2021 May 31;63(1625):81-3 | Show Introduction Hide Introduction

Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
Tirbanibulin 1% Ointment (Klisyri) for Actinic Keratosis Tirbanibulin, a microtubule inhibitor ...
Tirbanibulin, a microtubule inhibitor, has been approved by the FDA as a 1% ointment (Klisyri – Almirall) for topical treatment of actinic keratosis of the face or scalp.
Med Lett Drugs Ther. 2021 May 3;63(1623):70-1 | Show Introduction Hide Introduction

Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 2018  (Issue 1539)
Semaglutide (Ozempic) – Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes The FDA ...
The FDA has approved semaglutide (Ozempic – Novo Nordisk), a long-acting injectable GLP-1 (glucagon-like peptide-1) receptor agonist, for once-weekly treatment of adults with type 2 diabetes. It is the sixth GLP-1 receptor agonist to be approved in the US.
Med Lett Drugs Ther. 2018 Jan 29;60(1539):19-21 | Show Introduction Hide Introduction

Dolutegravir/Lamivudine (Dovato) - A Two-Drug Complete Regimen for HIV-1 Infection

   
The Medical Letter on Drugs and Therapeutics • Aug 26, 2019  (Issue 1579)
Dolutegravir/Lamivudine (Dovato) — A Two-Drug Complete Regimen for HIV-1 Infection The FDA has ...
The FDA has approved Dovato (ViiV), a fixed-dose combination of the integrase strand transfer inhibitor (INSTI) dolutegravir (Tivicay) and the nucleoside reverse transcriptase inhibitor (NRTI) lamivudine (Epivir, and generics), as a once-daily complete regimen for treatment of adults with HIV-1 infection who are antiretroviral-treatment naive and have no known substitutions associated with resistance to either drug. Dolutegravir/lamivudine is the first complete regimen to be approved by the FDA for initial treatment of HIV-1 infection that contains 2 rather than 3 antiretroviral drugs....
Med Lett Drugs Ther. 2019 Aug 26;61(1579):134-6 | Show Introduction Hide Introduction

Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes

   
The Medical Letter on Drugs and Therapeutics • Feb 25, 2019  (Issue 1566)
Cardiovascular Benefits of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Type 2 Diabetes Since ...
Since 2008, because of safety concerns, the FDA has mandated that long-term cardiovascular outcomes trials be conducted for all new drugs for type 2 diabetes. Reductions in the incidence of macrovascular complications in these trials with some sodium-glucose co-transporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor agonists in patients at risk for cardiovascular disease (see Table 1) have led to new recommendations.
Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-8 | Show Introduction Hide Introduction

Two New Doses of Dulaglutide (Trulicity) for Diabetes

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020  (Issue 1609)
Two New Doses of Dulaglutide (Trulicity) for Diabetes Table 1. Results of AWARD-111 A1C Change ...
The FDA has approved two additional doses (3 mg and 4.5 mg) of the glucagon-like peptide-1 (GLP-1) receptor agonist dulaglutide (Trulicity – Lilly) for treatment of type 2 diabetes in adults. Dulaglutide has been available in 0.75- and 1.5-mg doses for years.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):168 | Show Introduction Hide Introduction

Comparison Chart: SGLT2 Inhibitors (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 2020  (Issue 1611)
-TRANSPORTER 2 (SGLT2) INHIBITORS RENAL DOSAGE ADJUSTMENTS CANAGLIFLOZIN eGFR 30 to ...
View the Comparison Chart: SGLT2 Inhibitors
Med Lett Drugs Ther. 2020 Nov 16;62(1611):e184-188 | Show Introduction Hide Introduction

In Brief: New Meningococcal Serogroup B Vaccination Recommendations

   
The Medical Letter on Drugs and Therapeutics • Nov 30, 2020  (Issue 1612)
on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination.1 Booster ...
The Advisory Committee on Immunization Practices (ACIP) has issued new recommendations for meningococcal vaccination. Booster vaccination against Neisseria meningitidis serogroup B (MenB) is now recommended in persons at increased risk for meningococcal disease (see Table 1). MenB booster doses were not recommended previously for any population.
Med Lett Drugs Ther. 2020 Nov 30;62(1612):191-2 | Show Introduction Hide Introduction

In Brief: New Warnings for Janus Kinase Inhibitors

   
The Medical Letter on Drugs and Therapeutics • Oct 04, 2021  (Issue 1634)
events, malignancy, thrombosis, and death with their use.1 The new warnings were prompted ...
The FDA has required updates to the boxed warnings in the labeling of the Janus kinase (JAK) inhibitors tofacitinib (Xeljanz, Xeljanz XR), baricitinib (Olumiant), and upadacitinib (Rinvoq) describing increased risks of major adverse cardiovascular events, malignancy, thrombosis, and death with their use. The new warnings were prompted by the results of a postmarketing safety trial with tofacitinib and were added to the labels of baricitinib and upadacitinib based on the presumption of a class effect. The tofacitinib package insert had contained a boxed warning about an increased risk of...
Med Lett Drugs Ther. 2021 Oct 4;63(1634):160 | Show Introduction Hide Introduction